CRIS Current Research Information System

MANCUSO, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.170
NA - Nord America 3.574
EU - Europa 2.480
SA - Sud America 298
AF - Africa 295
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.828
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.489
VN - Vietnam 1.524
CN - Cina 1.332
SG - Singapore 1.168
IT - Italia 823
GB - Regno Unito 333
HK - Hong Kong 270
DE - Germania 257
KR - Corea 233
BR - Brasile 225
SE - Svezia 207
BD - Bangladesh 185
IN - India 172
NL - Olanda 172
FR - Francia 161
CI - Costa d'Avorio 118
FI - Finlandia 116
RU - Federazione Russa 89
IE - Irlanda 75
JP - Giappone 73
ZA - Sudafrica 63
SC - Seychelles 46
CA - Canada 40
UA - Ucraina 35
TG - Togo 34
AR - Argentina 33
PH - Filippine 33
BG - Bulgaria 32
MX - Messico 31
AT - Austria 30
TH - Thailandia 30
BE - Belgio 27
ES - Italia 23
EE - Estonia 21
TW - Taiwan 21
PL - Polonia 20
ID - Indonesia 19
CH - Svizzera 18
IQ - Iraq 18
JO - Giordania 18
CO - Colombia 11
SA - Arabia Saudita 11
AU - Australia 9
EC - Ecuador 9
NG - Nigeria 9
PK - Pakistan 9
TR - Turchia 8
CZ - Repubblica Ceca 6
UZ - Uzbekistan 6
CL - Cile 5
DZ - Algeria 5
IR - Iran 5
LT - Lituania 5
EG - Egitto 4
GR - Grecia 4
MA - Marocco 4
MY - Malesia 4
NP - Nepal 4
PT - Portogallo 4
RO - Romania 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
KE - Kenya 3
KZ - Kazakistan 3
LB - Libano 3
MT - Malta 3
OM - Oman 3
PE - Perù 3
PY - Paraguay 3
RS - Serbia 3
TN - Tunisia 3
UY - Uruguay 3
BO - Bolivia 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GH - Ghana 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
KG - Kirghizistan 2
LV - Lettonia 2
NO - Norvegia 2
PS - Palestinian Territory 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BS - Bahamas 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
ET - Etiopia 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
Totale 11.818
Salva come PNG Salva come JPEG
Città #
Singapore 822
Hefei 475
Ashburn 470
Ho Chi Minh City 422
Hanoi 334
San Jose 283
Chandler 275
Hong Kong 259
Southend 236
Seoul 220
Bologna 217
Dallas 208
Fairfield 199
Abidjan 118
Beijing 118
Ann Arbor 115
Woodbridge 107
New York 106
Seattle 96
Wilmington 88
Santa Clara 85
Houston 83
Los Angeles 82
Helsinki 77
Lauterbourg 75
Dublin 71
Boardman 69
Cambridge 63
Council Bluffs 63
Haiphong 59
Princeton 58
Tokyo 58
Dong Ket 57
Milan 55
Bengaluru 46
São Paulo 45
Buffalo 41
Frankfurt am Main 40
Hyderabad 38
Munich 36
Da Nang 35
Lomé 34
Johannesburg 30
Lappeenranta 30
Sofia 30
Turin 30
Bremen 27
Guangzhou 27
Brussels 25
Amsterdam 23
Rome 23
Fabriano 22
Florence 22
Westminster 22
Vienna 21
Berlin 20
Can Tho 20
Chicago 20
Jinan 20
Padova 20
Redondo Beach 20
Atlanta 19
Amman 18
Dongguan 18
London 18
Nanjing 18
Nuremberg 18
Redmond 18
Shenzhen 18
Biên Hòa 17
Ninh Bình 17
Quận Bình Thạnh 17
Changsha 16
Mexico City 16
Shanghai 16
Hải Dương 15
San Diego 15
Thái Nguyên 15
Ha Long 14
Tianjin 14
Tongling 14
Brooklyn 13
Phoenix 13
Warsaw 13
Jacksonville 12
Jakarta 12
Paris 12
Zhengzhou 12
Bern 11
Nanchang 11
Bắc Giang 10
Bắc Ninh 10
Falkenstein 10
Falls Church 10
Montreal 10
Redwood City 10
San Francisco 10
Shenyang 10
Toronto 10
Wuhan 10
Totale 7.430
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 711
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 349
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 270
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 249
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 247
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 236
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 230
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 214
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 211
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 210
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 210
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 209
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 209
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 208
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 204
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 202
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 199
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 198
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 197
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 190
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 189
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 189
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 184
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 179
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 178
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 178
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 177
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 177
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 175
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 171
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 166
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 163
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 160
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma 158
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature 157
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 155
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 153
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 153
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 152
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents 152
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 150
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 141
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 140
Role of consolidation therapy in transplant eligible multiple myeloma patients. 137
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 132
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 131
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 131
Pomalidomide combinations are a safe and effective option after daratumumab failure 130
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 129
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients 125
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 120
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 119
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 118
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 117
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 117
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 110
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 109
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 100
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 99
null 98
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 96
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 94
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS 93
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 92
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 88
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 87
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 84
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 81
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 73
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 70
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy 70
Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma 68
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial 63
Belamaf: Is Renal Toxicity an Overlooked Side Effect? 61
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients 57
Correction: Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 54
VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation 44
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study 41
Totale 12.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.872
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.872
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021138 0 0 0 0 0 0 0 0 0 0 0 138
2021/2022748 70 38 42 70 58 23 18 53 29 92 126 129
2022/20231.010 83 140 36 151 74 96 27 56 164 28 98 57
2023/2024455 29 40 25 36 26 91 16 91 11 35 37 18
2024/20251.867 110 167 153 135 127 66 133 64 55 222 214 421
2025/20266.585 575 1.130 569 578 507 312 511 250 1.086 451 327 289
Totale 12.088